On the enzymatic degradation of enkephalins: pharmacological implications.

A. Carenzi,I. Biasini,V. Frigeni,D. Della Bella

Abstract:

What problem does this paper attempt to address?

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Xiao-Jun Xu,Yong-Min Tang

DOI: https://doi.org/10.1016/j.canlet.2013.10.004

IF: 9.756

2014-01-01

Cancer Letters

Abstract:Adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells is a promising therapy for cancers. However, the safety of this approach is concerned. Cytokine release syndrome (CRS) is a common but lethal complication of CAR-T cell therapy. The development of CRS correlates with CAR structures, tumor type and burden, and patients' genetic polymorphisms. CRS related adverse events may be reduced by designing safer CARs and CAR-T cells and following strict dose-escalation scheme. Timely and effective cytokine-directed treatment with corticosteroid and various cytokine antagonists is important to avoid CRS associated death.
Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletion

Zuqiong Xu,Fang Tian,Biqing Chen,Xiangtu Kong,Xingbin Dai,Jiang Cao,Pengjun Jiang,Jianxin Tan,Lu Lu,Xiachang Wang,Qi Lv,Di Kang,Miao Xu,Yingying Hu,Aiping Yang,Qian Wang,Zhong-Fa Yang,Xuemei Sun,Leyuan Ma,Lihong Hu,Xuejun Zhu

DOI: https://doi.org/10.1101/2020.11.22.20232801

2020-01-01

Abstract:Background Cytokine release syndrome (CRS) is a potentially life-threatening complication of chimeric antigen receptor T (CAR-T) cell therapy. Recent studies indicated critical roles of macrophages and monocytes in CAR-T induced CRS. Here, we report rapid dissipation of CAR-T induced CRS in two patients after receiving Tripterygium glycosides (TG). Effects of triptolide, the major active component of TG, on macrophages and monocytes were examined in animal models. Methods Two patients with CRS after CAR-T cell therapy (for hematological malignancy) received TG (50 mg, p.o.). Flow cytometry analysis and single cell RNA sequencing (scRNAseq) were conducted to examine the effects of TG on immune cells. Potential effects of triptolide were also examined ex vivo using patient-derived monocytes, as well as in mice. Findings Rapid alleviation of fever and cytokine storm was observed within 72 hours after TG treatment. Blood concentration of triptolide ranged from 21 to 154 ng/mL during treatment. Flow cytometry and scRNAseq showed selective depletion of monocytes with minimal impact on CAR-T cells in both patients. In ex vivo experiments with patient-derived monocytes, triptolide dramatically inhibited the synthesis of pro-inflammatory cytokines (e.g., IL-6, IL-10, and IP-10). Triptolide also rapidly and selectively depleted peritoneal concanavalin A activated macrophages and monocytes in mice. Interpretation TG could be a promising treatment for CAR-T induced CRS, as well as other diseases with similar mechanisms, e.g., hemophagocytic lymphohistiocytosis and COVID-19. Our preliminary findings require further verification with properly designed clinical trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR-OIC-17013081,ChiCTR1900028098,ChiCTROIC-17011272 ### Funding Statement This study was supported in part by the Science and Technology Development Program of Jiangsu Province-Clinical Frontier Technology (grant Nos. BE2016809, BE2017639), the Nanjing Science and Technology Development Program (grant Nos. 201503011), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) (grant Nos. 035062002003c), and the development program of Jiangsu Provincial Hospital of Chinese Medicine (grant Nos.Y19030, Y19066). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This research has been approved by Institutional Review Board of Affiliate Hospital of Nanjing University of Chinese Medicine. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data are available upon request by emailing to zhuxuejun{at}njucm.edu.cn.
CAR-T cell-induced cytokine release syndrome is rapidly alleviated by tripterygium glycosides

Zhigao Xu,Fang Tian,Biqing Chen,Xiang-Tu Kong,Xianglin Dai,Jiang Cao,Pengjun Jiang,Lu Lu,Qi Lv,An‐Gang Yang,Leyuan Ma,Lihong Hu,Xulong Zhu

DOI: https://doi.org/10.21203/rs.3.rs-2331958/v1

2022-01-01

Abstract:Abstract Background Cytokine release syndrome (CRS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Macrophages/ monocytes are mediators of CRS. Tripterygium glycosides is an immunomodulator which could inhibit macrophages/ monocytes in animal models. Methods Two patients with relapsed and refractory hematological malignancies developed CRS after receiving CAR-T therapy. They received short-term tripterygium glycosides orally. Results Both patients showed rapid mitigation of fever with evidently decrease in elevated inflammatory cytokines within 72 hours. The patients' monocytes diminished remarkably, while CAR-T cells were neglectably affected. Treatment of 30 ng/mL triptolide in ex vivo cultured patients' blood for 24 hours selectively deplete over half of monocytes. Single cell RNA sequencing suggested selective depletion of CD14 + CD16 + monocytes with decreased pro-inflammatory cytokines. Conclusions The low-cost and orally available tripterygium glycosides could be a promising alternative for CAR-T induced CRS, as well as other diseases complicated with CRS, e.g., coronavirus disease 2019.
Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.

Neal Shiv Chawla,Samantha Jeffrey,Nadezhda Omelchenko,Rheanna Carter,Anmol Dia Agarwal,Ishrat Buhyian,William H. Isacoff,Michael Morse,William Swaney,Sant P. Chawla,Frederick L. Hall,Erlinda Maria Gordon

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e15086

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:e15086 Background: Expanded access for DeltaRex-G, a tumor targeted retrovector encoding a CCNG1 inhibitor, is being studied for advanced cancers. Methods: 137 archived tumor specimens were analyzed with AI RNA sequencing to identify CCNG1 expression levels, reported as: Low = 17%, Medium-low = 17%-49%, Medium-high = 50%-83%, High = 83%. Nine patients with advanced solid malignancies, whose CCNG1 levels were identified, received DeltaRex-G (2-3 x 10e11 cfu/dose one to three times a week), either without an FDA-approved drug, or with an FDA-approved drug (“DeltaRex-G Plus”). Overall survival, duration of treatment, and responses were evaluated. Results: All analyzed tumors showed enhanced CCNG1 expression. Thirty (22%) tumors exhibited High CCNG1 expression, 48 (35%) showed Medium-High CCNG1 expression, 53 (39%) displayed Medium-Low CCNG1 expression, and six (4%) had Low CCNG1 expression. One hundred (73%) patients had metastatic disease, and 37 (27%) had localized disease. There was no correlation between CCNG1 expression and disease stage. Four patients with advanced pancreatic cancer (n = 1), Stage 1 HR+Her2+ invasive breast cancer (n = 1), Stage 1 triple negative breast cancer (n = 1), and squamous cell carcinoma of skin (n = 1), received DeltaRex-G alone or DeltaRex-G Plus between 2008 and 2021 and are alive 15, 3, 2.5, and 2.5 years since treatment initiation, respectively. Retrospective analysis of their respective tumors showed CCNG1 expression levels of 24%, 23%, 74%, and 40%. Three of the patients are in sustained remission and the patient with squamous cell carcinoma had a partial response. Of the five patients currently being treated with DeltaRex-G Plus: one patient with advanced breast cancer had a partial response (n = 1), one patient with advanced pancreatic cancer (n = 1) and three patients with soft tissue sarcoma (n = 3) had stable disease. Four of five patients had previously progressed with standard doses of chemotherapy. All patients are alive from 11 to 22 weeks since treatment initiation. No serious treatment-related adverse events have been reported. Conclusions: Taken together, the data shows that (1) 100% of 137 tumors tested have enhanced CCNG1 expression, further reinforcing the 2021 FDA-CBER authorization for use of DeltaRex-Plus, and (2) DeltaRex-G Plus is a promising therapy for advanced pancreatic cancer, sarcoma, and breast cancer. Randomized Phase 2/3 studies are warranted to confirm the efficacy and safety of DeltaRex-G Plus. Clinical trial information: NCT04091295 .

oncology
Predictive Role of Endothelial Cell Activation in Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukaemia

Fei Hong,Ming Shi,Jiang Cao,Ying Wang,Yanqing Gong,Hui Gao,Zhenyu Li,Junnian Zheng,Lingyu Zeng,Aili He,Kailin Xu

DOI: https://doi.org/10.1111/jcmm.17029

2021-01-01

Journal of Cellular and Molecular Medicine

Abstract:CD19-target chimeric antigen receptor (CAR)-T cell therapy is highly effective for relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL), but is often complicated by cytokine release syndrome (CRS), which is potentially life-threatening. Endothelial cells are the core regulator of CRS in many infectious diseases and may also play a key role after CAR-T cell therapy. We provided a detailed clinical, laboratory description and endothelial cell activation biomarkers in patients with CRS. Endothelial cell activation was associated with occurrence, development and severity of CRS, manifested by decreased serum angiopoietin (Ang)-1 levels and increased levels of von Willebrand Factor (VWF), Ang-2, Ang-2:Ang-1, sE-selectin, soluble intercellular adhesion molecule (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM)-1. Besides, the endothelial activation was correlated with the hepatic, kidney and hematopoietic dysfunction in CRS patients. After infusion of CAR-T cells, we detected changes of endothelial activation-related biomarkers within 36 hours in patients who subsequently developed CRS, especially severe CRS. Using top tree models, we could predict which patients would develop CRS, especially severe CRS, or identify the severity of CRS by certain biomarkers of endothelial activation. These data provide a new idea and will help identify new targets for early intervention and prevention of CRS.
[Cutaneous leishmaniasis in the Fleuve region (Senegal, West Africa). Evaluation of the degree of immunity in the human population].

J. Dedet,J. Lemasson,J. Martin,F. Pradeau,A. Veys

1979-03-01

Abstract:
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A Gardner,Francesco Ceppi,Julie Rivers,Colleen Annesley,Corinne Summers,Agne Taraseviciute,Juliane Gust,Kasey J Leger,Katherine Tarlock,Todd M Cooper,Olivia C Finney,Hannah Brakke,Daniel H Li,Julie R Park,Michael C Jensen

DOI: https://doi.org/10.1182/blood.2019001463

IF: 20.3

2019-12-12

Blood

Abstract:Immunotherapy with the adoptive transfer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute lymphoblastic leukemia (ALL) can salvage >80% of patients having relapsed/refractory disease. The therapeutic index of this emerging modality is attenuated by the occurrence of immunologic toxicity syndromes that occur upon CAR T-cell engraftment. Here, we report on the low incidence of severe cytokine release syndrome (CRS) in a subject treated with a CAR T-cell product composed of a defined ratio CD4:CD8 T-cell composition with a 4-1BB:zeta CAR targeting CD19 who also recieved early intervention treatment. We report that early intervention with tocilizumab and/or corticosteroids may reduce the frequency at which subjects transition from mild CRS to severe CRS. Although early intervention doubled the numbers of subjects dosed with tocilizumab and/or corticosteroids, there was no apparent detrimental effect on minimal residual disease-negative complete remission rates or subsequent persistence of functional CAR T cells compared with subjects who did not receive intervention. Moreover, early intervention therapy did not increase the proportion of subjects who experience neurotoxicity or place subjects at risk for infectious sequelae. These data support the contention that early intervention with tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on the antitumor potency of CD19 CAR T cells. This intervention serves to enhance the therapeutic index in relapsed/refractory patients and provides the rationale to apply CAR T-cell therapy more broadly in ALL therapy. This trial was registered at www.clinicaltrials.gov as #NCT020284.
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Eduardo Huarte,Roddy S O'Connor,Michael T Peel,Selene Nunez-Cruz,John Leferovich,Ashish Juvekar,Yan-Ou Yang,Lisa Truong,Taisheng Huang,Ahmad Naim,Michael C Milone,Paul A Smith

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1739

2020-12-01

Abstract:Purpose: T cells engineered to express a chimeric antigen receptor (CAR) are a promising cancer immunotherapy. Such targeted therapies have shown long-term relapse-free survival in patients with B-cell leukemia and lymphoma. However, cytokine release syndrome (CRS) represents a serious, potentially life-threatening side effect often associated with CAR T-cell therapy. CRS manifests as a rapid (hyper)immune reaction driven by excessive inflammatory cytokine release, including IFNγ and IL6. Experimental design: Many cytokines implicated in CRS are known to signal through the JAK-STAT pathway. Here we study the effect of blocking JAK pathway signaling on CAR T-cell proliferation, antitumor activity, and cytokine levels in in vitro and in vivo models. Results: We report that itacitinib, a potent, selective JAK1 inhibitor, was able to significantly and dose-dependently reduce levels of multiple cytokines implicated in CRS in several in vitro and in vivo models. Importantly, we also report that at clinically relevant doses that mimic human JAK1 pharmacologic inhibition, itacitinib did not significantly inhibit proliferation or antitumor killing capacity of three different human CAR T-cell constructs (GD2, EGFR, and CD19). Finally, in an in vivo model, antitumor activity of CD19-CAR T cells adoptively transferred into CD19+ tumor-bearing immunodeficient animals was unabated by oral itacitinib treatment. Conclusions: Together, these data suggest that itacitinib has potential as a prophylactic agent for the prevention of CAR T cell-induced CRS, and a phase II clinical trial of itacitinib for prevention of CRS induced by CAR T-cell therapy has been initiated (NCT04071366).
Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models

Arezoo Jamali,Naphang Ho,Angela Braun,Elham Adabi,Frederic B Thalheimer,Christian J Buchholz

DOI: https://doi.org/10.1038/s44321-024-00055-9

2024-03-21

EMBO Molecular Medicine

Abstract:Abstract Cytokine release syndrome (CRS) is a significant side-effect of conventional chimeric antigen receptor (CAR) T-cell therapy. To facilitate patient accessibility, short-term (st) CAR T cells, which are administered to patients only 24 h after vector exposure, are in focus of current investigations. Their impact on the incidence and severity of CRS has been poorly explored. Here, we evaluated CD19-specific stCAR T cells in preclinical models. In co-culture with tumor cells and monocytes, stCAR T cells exhibited anti-tumoral activity and potent release of CRS-related cytokines (IL-6, IFN-γ, TNF-α, GM-CSF, IL-2, IL-10). When administered to NSG-SGM3 mice, stCAR T cells, but not conventional CAR T cells, induced severe acute adverse events within 24 h, including hypothermia and weight loss, as well as high body scores, independent of the presence of tumor target cells. Human (IFN-γ, TNF-α, IL-2, IL-10) and murine (MCP-1, IL-6, G-CSF) cytokines, typical for severe CRS, were systemically elevated. Our data highlight potential safety risks of rapidly manufactured CAR T cells and suggest NSG-SGM3 mice as sensitive model for their preclinical safety evaluation.

medicine, research & experimental
Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Ye Wei,Chong Li,Huifang Bian,Wei Qian,Kairui Jin,Tingting Xu,Xiaomao Guo,Xueguan Lu,Fengtao Su

DOI: https://doi.org/10.1186/s12943-020-01301-7

IF: 37.3

2021-01-04

Molecular Cancer

Abstract:Abstract Background Cytokine release syndrome (CRS) is a systemic inflammatory response characterized by the overexpression of inflammatory genes. Controlling CRS is essential for improving the therapeutic effects of chimeric antigen receptor (CAR) engineered T cells. However, current treatment options are limited given the complexity of cytokine interactions so it is important to seek a mild strategy with broad-spectrum inhibition to overcome this challenge. Methods Using THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), we demonstrated the transcriptional suppression of inflammatory genes in activated macrophages. RNA sequencing and ChIP sequencing were conducted to identify the key target genes of the inflammatory response. Pathogen- and CAR T cell-induced CRS models were also established to assess the efficacy and safety of targeting CDK7. Results CDK7 blockade attenuated cytokine release, mitigated hyperinflammatory states and rescued mice from lethal CRS. Targeting CDK7 preferentially suppressed a set of inflammatory genes, of which STAT1 and IL1 were the key targets associated with super enhancers. Furthermore, we confirmed the potent efficacy of THZ1 in alleviating the CRS induced by CAR T cell infusion without causing tissue injury or impairing antitumor effects. Conclusions Our work indicates the CDK7-dependent transcription addiction of inflammatory genes. Targeting CDK7 is a promising strategy for treating CRS by inhibiting multiple cytokines.

oncology,biochemistry & molecular biology
Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Xiaodi Zhang,Yuying Guo,Yinghua Ji,Yan Gao,Min Zhang,Yanting Liu,Wuling Zhu,Ping Lu

DOI: https://doi.org/10.1177/09636897221094244

2022-05-05

Cell Transplantation

Abstract:Cell Transplantation, Volume 31, Issue , January-December 2022. Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years. Among them, the CAR-NK (natural killer) therapy has shown better efficacy, and less toxicity, than chimeric antigen receptor T-cell (CAR-T) therapy. In our phase II clinical trials, administering chimeric costimulatory converting receptor (CCCR)-NK92 cells on advanced non-small cell lung cancer patients proved efficacious in cell and animal experiments. However, we observed occurrence of cytokine release syndrome (CRS), a rare and unexpected side effect, never reported before during CAR-NK therapy. Here, we provide a detailed report of the patient's case, emphasize on the need to pay attention to CRS in NK cell therapy, and suggest improvements that will minimize potential toxicity.

medicine, research & experimental,transplantation,cell & tissue engineering
Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Xue Wang,Lina Zhao,Jing Wang,Yue Yao,Jiaojiao Wang,Shengwei Ji,Tian Hua,Shiyuan Wang,Hai Cheng,Ming Shi,Zhenyu Li,Lingyu Zeng,Junnian Zheng,Kailin Xu,Jiang Cao

DOI: https://doi.org/10.3389/fimmu.2022.814548

IF: 7.3

2022-04-27

Frontiers in Immunology

Abstract:Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory multiple myeloma (R/R MM), the severity of cytokine release syndrome (CRS) can affect patient survival and the risk factors for CRS remain an intractable issue. We enrolled 54 patients with R/R MM following combined infusion of anti-CD19 and anti-B-cell maturation antigen (BCMA) CAR-T cells. The results showed the overall response rate was 94% (51/54) after CAR-T cell infusion, with a 100% incidence of CRS, including 47 patients with grade 1-2 (mild) CRS and 7 patients with grade 3-5 (severe) CRS. In the mild CRS group, the median progression-free survival (PFS) was 18.2 months (95% CI, 6.5 to 30.1) and the median overall survival (OS) was not reached yet. In the severe CRS group, median PFS and median OS were 1.9 months (95% CI, 0.2 to 3.8). Further analysis demonstrated that severe CRS had a shorter median PFS and OS than mild CRS ( p =0.029, p =0.020). Bone marrow tumor burden was found to be independently associated with CRS. The grade of CRS was positively correlated with six serum cytokines levels including G-CSF, IL-6, IL-8, IP-10, MIP-1a and RANTES. In conclusion, early detection and management of CRS are imperative for the prevention of life-threatening complications and improvement in the survival of patients of CAR-T cell therapy. Clinical Trial Registration: www.chictr.org.cn, identifier ChiCTR-OIC-17011272.

immunology
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel

Xianlei Li,Ningqiang Gong,Falin Tian,Shangkun Zhang,Yuxuan Zhang,Yufei Wang,Guangchao Qing,Yongchao Wang,Fangzhou Li,Yihui Xu,Linlin Zhang,Jinjin Wang,Qiankun Ni,Yaling Gan,Chaojiang Gu,Huaidong Jiang,Xingxu Huang,Xinghua Shi,Tongcun Zhang,Yan Wu,Xing-Jie Liang

DOI: https://doi.org/10.1038/s41551-023-01084-4

IF: 28.1

2023-09-11

Nature Biomedical Engineering

Abstract:The infusion of chimaeric antigen receptor (CAR) T cells can trigger the release of life-threatening supraphysiological levels of pro-inflammatory cytokines. However, uncertainty regarding the timing and severity of such cytokine release syndrome (CRS) demands careful monitoring of the conditions required for the administration of neutralizing antibodies. Here we show that a temperature-sensitive hydrogel conjugated with antibodies for the pro-inflammatory cytokine interleukin-6 (IL-6) and subcutaneously injected before the infusion of CAR-T cells substantially reduces the levels of IL-6 during CRS while maintaining the therapy’s antitumour efficacy. In immunodeficient mice and in mice with transplanted human haematopoietic stem cells, the subcutaneous IL-6-adsorbing hydrogel largely suppressed CAR-T-cell-induced CRS, substantially improving the animals’ survival and alleviating their levels of fever, hypotension and weight loss relative to the administration of free IL-6 antibodies. The implanted hydrogel, which can be easily removed with a syringe following a cooling-induced gel–sol transition, may allow for a shift in the management of CRS, from monitoring to prevention.

engineering, biomedical
The Interim Analysis of a First-in-human Phase 1 Trial of ET-901, a CRISPR Edited Allogeneic Immune-Cloaked Anti-Cd19 CAR-T Cell Therapy in Patients with R/r B-NHL.

Yang Liu,Jinhong Shi,Qingming Yang,Chunmeng Wang,Feifei Liang,Zeguang Wu,Qiezhong Lamao,Jinxin Yang,Yuanyuan Qiu,Wei Tang,Haixia Zhang,Zhonghan Yang,Ling Yang,Yongjian Zhang,Ming Jin,Pengfei Yuan,Wensheng Wei,Weidong Han

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e19010

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e19010 Background: Allogeneic CAR T-cell therapy faces challenges like limited persistence and host rejection. Current research has improved its viability by modifying genes like B2M, despite new challenges like NK cell targeting have emerged. Through CRISPR screening, we discovered a novel gene, named GeneX, and its role in enhancing T cell persistence against allogeneic attacks and AICD. GeneX influences glycan composition, affecting immune responses and AICD initiation. Engineered GeneXKO/TCRKO/anti-CD19 CAR T cells (ET-901) resisted allogeneic killing and maintained anti-tumor effects without causing GvHD, marking a significant advancement in CAR T-cell therapy. Methods: ET-901 is being tested in a phase 1 trial for r/r B-NHL at a single center, utilizing a 3+3 dose escalation scheme and planning for expansion at the recommended Phase 2 dose. Participants must have an ECOG status of 0–2, without a history of allo-HSCT or CAR-T therapy. The study's main goals are to assess ET-901's safety and establish the optimal Phase 2 dosage. Patients undergo a 3-day lymphodepletion with fludarabine (30-50 mg/m2/d) and cyclophosphamide (500-1000 mg/m2/d), followed by a single-dose infusion of ET-901 at escalating doses (DL1:1*10e6/kg, DL2:3*10e6/kg, and DL3:10*10e6/kg). Pharmacokinetic monitoring occurs during follow-up. Results: From September 2023, a total of six patients were enrolled in the escalation cohort, including 4 patients with LBCL and 2 with FL. In these patients (3 males), the median age was 53 years (range: 46–55 years), and the median number of prior treatment lines was 5. The median SPD was 7,650 mm2 (range: 2,700-43,400 mm2). Notably, two cases in DL2 exhibited unusual lymphoma infiltration sites: patient No.4 in the forearm muscle and patient No.5 in the spleen. Update to February 2024, we have completed the safety evaluation of Dose Level (DL) 1 and DL2. No DLTs were observed. The most common TRAEs of any grade included leukopenia (6/6), granulocytopenia (6/6), anemia (6/6), thrombocytopenia (6/6), CRS (6/6), infection (2/6), ICANS (2/6), and GvH like reaction (1/6). All patients achieved objective responses, with 2 cases of PR and 4 cases of CR (1 in DL1, 3 in DL2). The peak values of CAR+ cells count and VCN in peripheral blood were 36.0/μl (range: 14.0-48.0/μl, median: day 7), and 9.6e4 copies/μg (range: 7.7e4-1.2e5 copies/μg, median: day 7), respectively. In all patients, a second expansion of CAR-T cells was observed alongside B cell recovery. This confirms that GeneX knockout enables allo CAR-T cells to maintain long-term immune privilege while preserving their biological function. Conclusions: The study demonstrated the safety and feasibility of ET-901 in patients with r/r B-NHL. These findings highlight the potential of ET-901 as an effective therapeutic approach for improving outcomes for these patients. Clinical trial information: NCT06014073 .
The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy

Vahid Mansouri,Niloufar Yazdanpanah,Nima Rezaei

DOI: https://doi.org/10.1080/08830185.2021.1984449

2021-10-05

International Reviews of Immunology

Abstract:Chimeric antigen receptor (CAR) T cells are the pioneers of cancer immunotherapy, which to this date have several FDA-approved products. They have been substantially improved since their first introduction in 1993 and have shown promising results regardless of their inevitable side effects. Cytokine release syndrome (CRS), the most common toxicity after CAR T cell treatment, is affiliated to a systemic inflammation through surge of cytokines, mainly IL-6, IL-1, and INF-γ. Furthermore, difference between histocompatibility antigens activates the graft versus host disease (GvHD) effect of the allogenic CAR T cells against the host cells. Immunological reactions induced by CAR T cells in the form of CRS or GvHD is necessary for fostering good responses, while excess reactions can potentially threaten patient life. In this review, we first describe the history, applications, and structure of CAR T cells, followed by a comprehensive review of CRS regarding its definition, management, and immunological aspects. Finally, we discuss about the clinical aspects of CRS and GvHD after CAR T cell therapy and how to harness anti-tumoral effects, while mitigating the adverse effects.Graphical
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy

Victor E. Tedesco,Chandra Mohan

DOI: https://doi.org/10.4049/jimmunol.2001249

2021-03-10

The Journal of Immunology

Abstract:Key Points<li>Toxicity risk can be identified early by tumor burden and fever characteristics.</li><li>Cytokine-based algorithms have excellent predictive power.</li>
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy

Meng-Yin Lin,Eunwoo Nam,Ryan M. Shih,Amanda Shafer,Amber Bouren,Melanie Ayala Ceja,Caitlin Harris,Mobina Khericha,Kenny H. Vo,Minsoo Kim,Chi-Hong Tseng,Yvonne Y. Chen

DOI: https://doi.org/10.1084/jem.20221988

2024-04-13

Journal of Experimental Medicine (JEM)

Abstract:Cytokine release syndrome (CRS) is a frequently observed side effect of chimeric antigen receptor (CAR)-T cell therapy. Here, we report self-regulating T cells that reduce CRS severity by secreting inhibitors of cytokines associated with CRS. With a humanized NSG-SGM3 mouse model, we show reduced CRS-related toxicity in mice treated with CAR-T cells secreting tocilizumab-derived single-chain variable fragment (Toci), yielding a safety profile superior to that of single-dose systemic tocilizumab administration. Unexpectedly, Toci-secreting CD19 CAR-T cells exhibit superior in vivo antitumor efficacy compared with conventional CD19 CAR-T cells. scRNA-seq analysis of immune cells recovered from tumor-bearing humanized mice revealed treatment with Toci-secreting CD19 CAR-T cells enriches for cytotoxic T cells while retaining memory T-cell phenotype, suggesting Toci secretion not only reduces toxicity but also significantly alters the overall T-cell composition. This approach of engineering T cells to self-regulate inflammatory cytokine production is a clinically compatible strategy with the potential to simultaneously enhance safety and efficacy of CAR-T cell therapy for cancer.
Abstract 3609: Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies

John R. Newcomb,Jun Ren,Sakeena Syed,Zachary Caruolo,Lindsay Webb,Craig McKay,Stephanie Kwei,Carl Novina,Fred Mermelstein

DOI: https://doi.org/10.1158/1538-7445.am2024-3609

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Cytokine activation of T cells can promote T cell proliferation, memory and improve T cell function in driving tumor cell killing. However, systemic administration of cytokines at therapeutic doses is also associated with unacceptable toxicities. To overcome this limitation, we have engineered a system of private cytokine signaling to affect T cell homeostasis, identity, and function. Specifically, we have engineered chimeric cytokine receptors (CCRs) composed of single-chain variable fragments (scFvs) that bind specifically to small molecules such as fluorescein or DOTA. These scFvs are fused to transmembrane and intracellular domains of all members of the common gamma-chain (γ-chain) family of cytokine receptors. CCRs that permit private cytokine signaling were introduced into known CAR-T cell therapies and their impact on CAR-T cell phenotype, function, and anti-tumor activity was tested. First, CCR-containing T cells were tested for activation-induced changes in phenotype and expansion following stimulation with small molecule conjugates in vitro. The most promising results were obtained using either the IL-7Rα- or IL-2Rβ/γ-containing CCR’s. CCR-containing constructs were then transduced into one of two different anti-BCMA CAR-T constructs, ide-cel or cilta-cel, using a lentiviral transduction system. CAR-T cells containing each CCR were then compared with CAR-T cells lacking CCRs for phenotype and function in vitro. Results indicated that engineering the IL-7Rα CCR with both of these CAR-T’s led to increased expansion, cytokine secretion and improved tumor cell killing. Next, CAR-T cells expressing the IL-7Rα CCR were compared to CAR-T cells lacking CCR for efficacy and durability in a mouse model of human multiple myeloma. IL-7Rα CCR-expressing CAR-T cells demonstrated improved long-term tumor control compared to ide-cel and cilta-cel alone. In addition, IL-7Rα CCR-expression increased T cell numbers in blood, spleen and bone marrow of tumor-bearing mice. These increases were particularly evident in the CD8+population of CAR-T cells in vivo. These results demostrate that private cytokine signaling using small-molecule activatable CCRs can improve efficacy and durability of CAR-T cells. We are testing these CCRs in mouse models of human solid tumors to assess their ability to overcome the immunosuppressive microenvironment. Citation Format: John R. Newcomb, Jun Ren, Sakeena Syed, Zachary Caruolo, Lindsay Webb, Craig McKay, Stephanie Kwei, Carl Novina, Fred Mermelstein. Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3609.

oncology
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Rawan Faramand,Michael Jain,Verena Staedtke,Hiroshi Kotani,Renyuan Bai,Kayla Reid,Sae Bom Lee,Kristen Spitler,Xuefeng Wang,Biwei Cao,Javier Pinilla,Aleksander Lazaryan,Farhad Khimani,Bijal Shah,Julio C. Chavez,Taiga Nishihori,Asmita Mishra,John Mullinax,Ricardo Gonzalez,Mohammad Hussaini,Marian Dam,Brigett D. Brandjes,Christina A. Bachmeier,Claudio Anasetti,Frederick L. Locke,Marco L. Davila

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1434

IF: 13.801

2020-09-16

Clinical Cancer Research

Abstract:Purpose: One of the challenges of adoptive T-cell therapy is the development of immune-mediated toxicities including cytokine release syndrome (CRS) and neurotoxicity (NT). We aimed to identify factors that place patients at high risk of severe toxicity or treatment-related death in a cohort of 75 patients with large B-cell lymphoma treated with a standard of care CD19 targeted CAR T-cell product (axicabtagene ciloleucel). Experimental Design: Serum cytokine and catecholamine levels were measured prior to lymphodepleting chemotherapy, on the day of CAR T infusion and daily thereafter while patients remained hospitalized. Tumor biopsies were taken within 1 month prior to CAR T infusion for evaluation of gene expression. Results: We identified an association between pretreatment levels of IL6 and life-threatening CRS and NT. Because the risk of toxicity was related to pretreatment factors, we hypothesized that the tumor microenvironment (TME) may influence CAR T-cell toxicity. In pretreatment patient tumor biopsies, gene expression of myeloid markers was associated with higher toxicity. Conclusions: These results suggest that a proinflammatory state and an unfavorable TME preemptively put patients at risk for toxicity after CAR T-cell therapy. Tailoring toxicity management strategies to patient risk may reduce morbidity and mortality.

oncology
[Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model]

J Q Shan,S F Nan,F Li,C Y Shen,Y Zhang

DOI: https://doi.org/10.3760/cma.j.cn112152-20190916-00598

2021-12-23

Abstract:Objective: To establish a cytokine release syndrome (CRS) mouse model related to CAR-T cell therapy and provide a research model for the clinical phenomena. Methods: CAR-T cells targeting human CD19 molecule were constructed by molecular cloning and lentiviral transfection. Flow cytometry (FACS) was used to detect the transfection efficiency of CAR-T cells. The tumor-killing efficiency of CAR-T cells was detected by ELISA and flow cytometry. The CAR-T cells were injected into the tumor-bearing SCID/Beige mice through tail vein, and divided into phosphate buffered solution (PBS) group, low-burden group (1×10(5) Raji-Luc2 cells) and high-burden group (5×10(5) Raji-Luc2 cells). The tumor treatment effect was detected by animal in vivo imaging. Serum levels of cytokines including human IFN-γ, human IL-2, mouse IL-6, and mouse GM-CSF were measured by ELISA. The health status of the mice was evaluated by pathological examination. Results: The health scores of T cell group and T cell+ OKT-3 group were (1.15±0.08) and (2.90±0.15), respectively, after the injection of human T cell and T cell + OKT-3 antibody through tail vein, and the difference was statistically significant (P<0.001). The serum levels of human IL-2, human IFN-γ, human IL-15, mouse IL-6 and mouse GM-CSF in T cell+ OKT-3 group were (1 064.00±50.14), (1 285.00±193.90), (202.4±18.76), (1 478.00±289.20) and (350.70±42.27) pg/ml, respectively, higher than (22.67±6.36), (23.67±3.71), (44.33±14.45), (147.30±36.20), (138.00±22.74) pg/ml in T cell group (P<0.05). OKT-3 combined with human T cells caused a rapid increase in serum levels of human IL-2, human IFN-γ, mouse IL-6 and mouse GM-CSF, accompanied by an increase in body temperature and weight loss. CD19-targeting CAR-T cells were successfully constructed, and the positive rate of CAR-T cells was >30% detected by flow cytometry. ELISA results showed that in the presence of CD19 antigen, IL-2 and IFN-γ secreted by CAR-T19 cells co-incubated with Raji and Nalm were (561.00±37.07), (680.30±71.27), (369±25.71) and (523.00±26.31) pg/ml, respectively, higher than (55.00±20.53) and (64.00±7.55) pg/ml in the co-incubated with K562 group (P<0.001). Activated CAR-T19 cells were reinjected through the tail vein on the seventh day after tumor formation. Imaging experiments in mice showed that on the thirteenth day after tumor formation, the fluorescence intensities of tumors in the low-burden and high-burden groups were lower than on the seventh day of tumor inoculation, and the fluorescence intensity of tumors in the high-burden group decreased from 144.00±24.69 to 5.02±2.35 (P=0.005). The fluorescence intensity of low burden group decreased from 58.47±9.36 to 3.48±1.67 (P=0.004). The serum levels of T cell activation related cytokines IL-2, IL-15 and IFN-γ increased rapidly, and the secretion of monocyte related cytokines IL-16 and GM-CSF increased, accompanied by the typical characteristics of CRS such as increased body temperature and weight loss at 72 hours after injection of CAR-T19 cells. Conclusions: CAR-T cells targeting CD19 molecule are successfully constructed, and CRS phenomenon is verified in tumor-bearing mice by CAR-T cell re-infusion, providing an animal model for the mechanism of CAR-T treatment-related CRS and CRS prevention strategies.

On the enzymatic degradation of enkephalins: pharmacological implications.

Cytokine Release Syndrome in Cancer Immunotherapy with Chimeric Antigen Receptor Engineered T Cells.

Tripterygium glycosides as a potential treatment for CAR-T induced cytokine release syndrome: implication of monocyte depletion

CAR-T cell-induced cytokine release syndrome is rapidly alleviated by tripterygium glycosides

Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.

Predictive Role of Endothelial Cell Activation in Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukaemia

[Cutaneous leishmaniasis in the Fleuve region (Senegal, West Africa). Evaluation of the degree of immunity in the human population].

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma

Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel

The Interim Analysis of a First-in-human Phase 1 Trial of ET-901, a CRISPR Edited Allogeneic Immune-Cloaked Anti-Cd19 CAR-T Cell Therapy in Patients with R/r B-NHL.

The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy

Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy

Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy

Abstract 3609: Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

[Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model]